Guess Which East Coast State Is Now Discussing Legalizing Psychedelics?

Decriminalizing psychedelics is one thing, but fully legalizing them is another.

That's currently a measure before New York's Senate Health Committee.

By prefiling the bill, Democratic sponsors Reps. Linda Rosenthal, Jo Anne Simon and Karines Reyes seek to gain more time to draft legislation and review bills prior to committee referral. 

As presented, the proposal seeks to amend current legislation towards legalizing the possession, use, cultivation, production, analysis, gifting and sharing of  “a natural plant or fungus-based hallucinogen” among adults 21 and older.

The bill refers to the legalization of DMT, ibogaine, mescaline, psilocybin and psilocin.

Employers would not be allowed to take adverse action against workers for using psychedelics off-duty nor would people lose professional licenses, public assistance or be denied mental health or behavioral health services for using psychedelics. 

For a closer look at the bill, Benzinga reached out to Joshua Kappel, founding partner of Vicente Sederberg LLP and head of the firm’s Entheogens and Emerging Therapies division. Continue reading here.

MDMA For PTSD Shows Positive Results In Important Clinical Trial

MAPS Public Benefit Corporation (MAPS PBC), the non-profit’s private biopharma leg developing psychedelic medicines, announced positive results from MAPP2, the company’s second Phase 3 study assessing MDMA-assisted therapy for PTSD

"The Phase 3 confirmatory results support the development of MDMA-assisted therapy as a potential new breakthrough therapy to treat individuals with PTSD. Now with two positive Phase 3 trials complete, we can add this important data to the new drug application which we expect to submit in the third quarter of …

Full story available on Benzinga.com